Her2 Targeted Therapy
Her2 Targeted Therapy - Related Videos
11:52
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
0 Views •
Cited by 1 •
2013
This article details the procedures for optical imaging analysis of the tumor-targeted nanoparticle, HerDox. In particular, detailed use of the multimode imaging device for detecting tumor targeting and assessing tumor penetration is described here.
02:57
Targeted Cancer Therapies
0 Views •
2021
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body. There are several types of targeted therapies against specific...
02:57
Targeted Cancer Therapies
0 Views •
2023
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body. There are several types of targeted therapies against specific...
08:03
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
0 Views •
Cited by 7 •
2016
Photodynamic therapy (PDT) is an alternative choice for lung cancer treatment. To increase the therapeutic effect of PDT, lung cancer-targeted nanoparticles combined with chemotherapy were developed. Both in vitro and in vivo anticancer efficacies of PDT with prepared nanoparticles were evaluated.
10:21
Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation
0 Views •
Cited by 3 •
2017
Fluorescence in-situ hybridization (FISH) is often required in combination with histopathology and molecular diagnostics for selection of therapy in personalized medicine. A novel non-cross-linking, formalin-free tissue fixative that allows high quality morphologic, molecular and FISH analyses from the same specimen by addition of a post-fixation step before FISH is presented.
FAQs
Monoclonal antibodies such as trastuzumab and pertuzumab bind HER2 on tumor cells, producing two complementary effects. They can disrupt receptor signaling linked to cell growth and survival, while also recruiting immune cells through antibody-dependent cellular cytotoxicity, or ADCC. This dual action makes the treatment relevant both to cancer-cell signaling and to immune-mediated elimination.
They address the same therapeutic target through different mechanisms. Kinase inhibitors block HER2-associated kinase activity, whereas drug-conjugate approaches deliver cytotoxic agents directly to HER2-positive cells. This distinction matters in cancer research because it allows investigators to compare signaling blockade with targeted payload delivery when designing treatment strategies for tumors selected through HER2-related biomarkers.
HER2 status connects a molecular feature of the tumor with treatment selection. Increased HER2 levels or gene amplification identify tumors that may be considered for therapies directed at this receptor. In research and clinical development, this biomarker-based approach supports precision treatment by linking the presence of the target to the choice of an appropriate therapeutic strategy.
ADCC provides an immune-mediated component in addition to direct receptor effects. When an antibody is bound to HER2, it can help recruit immune cells that damage the marked cancer cell. Thus, the antibody is not acting only as a signaling blocker; it can also connect target recognition with immune effector activity, an important mechanism when researchers evaluate antibody therapy.
Researchers first characterize the tumor for increased HER2 levels or amplification. That result provides the molecular basis for considering a HER2-directed approach rather than selecting therapy without a target-related rationale. Investigators can then compare available modalities, including antibodies, kinase inhibitors, or targeted cytotoxic delivery, according to the treatment strategy under study.
The overview identifies breast and gastric cancers as important settings for this approach. In these diseases, HER2-directed treatments have improved outcomes for some patients, while the underlying biomarker principle remains central: tumors are evaluated for the relevant HER2 alteration before a targeted strategy is considered. This makes the therapy a practical example of precision oncology.
HER2-targeted therapies provide a platform for testing personalized combinations because they can affect signaling, engage immune cells, or deliver cytotoxic agents through the same molecular target. Cancer researchers can investigate which treatment components best suit tumors with HER2 elevation or amplification, supporting the broader goal of refining individualized treatment plans and improving outcomes.